Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the response to Taxotere (docetaxel) chemotherapy
given as a primary treatment to patients with early and rapid PSA rising after prostatectomy
for high risk disease.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Québec, CHU de Québec CHU de Quebec-Universite Laval